Published in Veterinary and Comparative Oncology, this study by Chelsea M. Del Alcazar, J. Mahoney, K. Dittrich, D. Stefanovski, and M. Church characterizes the histological features, clinical behavior, and prognostic indicators of canine gastrointestinal sarcomas. These tumors—including leiomyosarcomas (LMSAs), gastrointestinal stromal tumors (GISTs), and rarer sarcomas—account for roughly 10–30% of all canine gastrointestinal tumors.
From a single-institution database, the researchers identified 47 surgically treated cases with adequate tissue for histological evaluation and 42 cases with available clinical outcome data. Tumors were assessed for mitotic count, necrosis, hemorrhage, inflammation, and were categorized with immunohistochemical staining for smooth muscle actin, c-KIT, and DOG-1. IHC findings classified 32 tumors as GISTs, 14 as LMSAs, and one as an unspecified sarcoma.
Across both GISTs and LMSAs, the median survival time (MST) was 1024 days (range 31–1456), with no significant difference between tumor types (p = 0.92). Metastatic rates were also comparable: 32.1% for GISTs and 15.3% for LMSAs, though the difference was not statistically significant (p = 0.45).
Multivariate analysis revealed two major prognostic factors associated with improved survival: (1) Mitotic count under 9 in dogs with GISTs, and (2) Complete surgical excision across all tumor types. These findings underscore the importance of accurate histopathological assessment and aggressive surgical management when feasible.
The study also identified an important biomarker: c-KIT staining intensity in GISTs. Dogs with weak c-KIT staining had an MST of 250 days, while those with moderate or strong staining had a dramatically longer MST of 1418 days (p = 0.005). This positive correlation between staining intensity and survival provides clinicians with a valuable tool for prognosis and treatment planning.
Overall, the research deepens understanding of the biological behavior of canine gastrointestinal sarcomas and highlights histological and surgical factors that meaningfully influence survival. These insights support more informed clinical decision-making and may guide future developments in diagnostic protocols, biomarker validation, and therapeutic strategies.
Source: Del Alcazar, C. M., Mahoney, J., Dittrich, K., Stefanovski, D., & Church, M. (2021). Outcome, prognostic factors, and histological characterization of canine gastrointestinal sarcomas. Veterinary and Comparative Oncology. Published March 27, 2021.
